Edwards Lifesciences Co. (NYSE:EW) is 2Xideas AG’s 10th Largest Position

2Xideas AG raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 25.9% during the first quarter, HoldingsChannel reports. The firm owned 196,508 shares of the medical research company’s stock after buying an additional 40,465 shares during the quarter. Edwards Lifesciences comprises 2.3% of 2Xideas AG’s holdings, making the stock its 10th largest position. 2Xideas AG’s holdings in Edwards Lifesciences were worth $18,778,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of EW. Norges Bank bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $648,540,000. Brown Advisory Inc. lifted its stake in Edwards Lifesciences by 20.1% in the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after purchasing an additional 3,048,274 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Edwards Lifesciences by 57.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after buying an additional 2,390,137 shares during the period. CIBC Private Wealth Group LLC grew its stake in shares of Edwards Lifesciences by 197.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock valued at $262,815,000 after buying an additional 2,286,119 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Edwards Lifesciences by 9.5% in the first quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock worth $1,813,089,000 after buying an additional 1,644,869 shares during the period. 79.46% of the stock is owned by institutional investors.

Insider Activity

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total value of $1,212,624.00. Following the completion of the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Bernard J. Zovighian purchased 580 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was bought at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the purchase, the chief executive officer now directly owns 3,268 shares in the company, valued at approximately $280,198.32. The disclosure for this purchase can be found here. Insiders have sold a total of 73,849 shares of company stock worth $6,381,503 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Down 0.2 %

EW traded down $0.10 during trading on Tuesday, hitting $63.64. The stock had a trading volume of 9,057,778 shares, compared to its average volume of 3,850,313. The stock has a 50 day simple moving average of $86.92 and a two-hundred day simple moving average of $86.84. The company has a market capitalization of $38.35 billion, a PE ratio of 27.43, a PEG ratio of 2.33 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter last year, the firm earned $0.66 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. On average, research analysts predict that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Analyst Ratings Changes

EW has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft dropped their price objective on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, July 25th. Baird R W cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Robert W. Baird lowered shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $102.00 to $70.00 in a report on Thursday, July 25th. Wells Fargo & Company lowered their price objective on shares of Edwards Lifesciences from $99.00 to $90.00 and set an “overweight” rating for the company in a research report on Thursday, July 25th. Finally, Truist Financial downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $110.00 to $82.00 in a research note on Thursday, July 25th. Fourteen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and an average price target of $82.10.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.